Conclusion
In summary, precision medicine has helped with better understanding of the biology and oncogenic mechanisms of lung cancer. This has led to a new foundation of rationally designed therapeutic regimens including targeted and immunotherapy, thus expanding the therapeutic landscape of lung cancer. These regimens have high efficacy and manageable toxicity profiles, which in turn has led to improved survival. With these new advancements, we are touching new horizons in lung cancer treatment and in near future it is expected that chemotherapy will not be commonly used and lung cancer patients will have longer and better quality of life.